Latest News about KALV
Recent news which mentions KALV
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%
October 06, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 05, 2022
From Benzinga
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday
October 05, 2022
From Benzinga
S&P 500 Rises 100 Points; Nasdaq Up 3%
October 04, 2022
From Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
From Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 04, 2022
From Benzinga
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
October 04, 2022
From Benzinga
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
October 04, 2022
Tickers
KALV
From InvestorPlace
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday
October 04, 2022
From Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
October 04, 2022
From Benzinga
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients
October 04, 2022
Tickers
KALV
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 04, 2022
From Benzinga
From InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
From Benzinga
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
August 23, 2022
Tickers
KALV
From Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
From Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
November 10, 2021
From Benzinga
Why KalVista Pharmaceuticals' Stock Is Trading Higher Today
September 15, 2021
Tickers
KALV
From Benzinga
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
September 14, 2021
Tickers
KALV
From Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
September 09, 2021
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.